See more : Shanghai Gench Education Group Limited (1525.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Mirum Pharmaceuticals, Inc. (MIRM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mirum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Banco de Valores S.A. (VALO.BA) Income Statement Analysis – Financial Results
- Concordia Financial Group, Ltd. (CCRDF) Income Statement Analysis – Financial Results
- Bodycote plc (BOY.L) Income Statement Analysis – Financial Results
- Etsy, Inc. (3E2.DE) Income Statement Analysis – Financial Results
- The Tirex Corporation (TXMC) Income Statement Analysis – Financial Results
Mirum Pharmaceuticals, Inc. (MIRM)
About Mirum Pharmaceuticals, Inc.
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 186.37M | 77.06M | 19.14M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 47.04M | 12.37M | 1.90M | 623.00K | 324.00K | 0.00 |
| Gross Profit | 139.34M | 64.69M | 17.24M | -623.00K | -324.00K | 0.00 |
| Gross Profit Ratio | 74.76% | 83.94% | 90.06% | 0.00% | 0.00% | 0.00% |
| Research & Development | 102.61M | 106.84M | 131.43M | 81.61M | 42.99M | 2.33M |
| General & Administrative | 139.58M | 16.96M | 59.22M | 22.69M | 11.75M | 877.50K |
| Selling & Marketing | 6.30M | 72.11M | 9.20M | 0.00 | 0.00 | -292.50K |
| SG&A | 145.88M | 89.07M | 59.22M | 22.69M | 11.75M | 585.00K |
| Other Expenses | 0.00 | 365.00K | 107.42M | -192.00K | -21.00K | 0.00 |
| Operating Expenses | 248.49M | 195.91M | 190.65M | 104.30M | 54.74M | 2.92M |
| Cost & Expenses | 295.53M | 208.28M | 192.55M | 104.30M | 54.74M | 2.92M |
| Interest Income | 13.74M | 3.86M | 366.00K | 1.56M | 2.23M | 87.00K |
| Interest Expense | 15.11M | 15.98M | 17.59M | 335.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 10.83M | 3.68M | 975.00K | 623.00K | 324.00K | 4.37M |
| EBITDA | -136.49M | -122.41M | -65.39M | -102.31M | -52.21M | -17.33M |
| EBITDA Ratio | -73.23% | -164.80% | -337.83% | 0.00% | 0.00% | 0.00% |
| Operating Income | -109.15M | -131.22M | -173.41M | -104.30M | -54.74M | -2.92M |
| Operating Income Ratio | -58.57% | -170.28% | -906.12% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -53.27M | -10.85M | 89.46M | 1.03M | 2.21M | -14.43M |
| Income Before Tax | -162.42M | -142.07M | -83.95M | -103.26M | -52.53M | -17.35M |
| Income Before Tax Ratio | -87.15% | -184.36% | -438.66% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 991.00K | -6.41M | 37.00K | 6.00K | 21.00K | -4.37M |
| Net Income | -163.42M | -135.67M | -83.99M | -103.27M | -52.55M | -17.35M |
| Net Income Ratio | -87.68% | -176.05% | -438.85% | 0.00% | 0.00% | 0.00% |
| EPS | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| EPS Diluted | -4.00 | -4.01 | -2.77 | -4.09 | -2.29 | -0.75 |
| Weighted Avg Shares Out | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
| Weighted Avg Shares Out (Dil) | 40.89M | 33.84M | 30.32M | 25.25M | 22.99M | 22.99M |
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Why Is Mirum Pharmaceuticals (MIRM) Down 3.4% Since Last Earnings Report?
Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older
Long-Term Data from Mirum's LIVMARLI Studies in ALGS and PFIC to be Presented at EASL Congress
Mirum's (MIRM) Livmarli Aids Sales but Overdependence Concerns
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
Source: https://incomestatements.info
Category: Stock Reports